Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: A pilot study

American Journal of Respiratory and Critical Care Medicine

Volumn 167, Issue 12, 2003, Pages 1655-1659

  Kips, Johan C ^a   O'Connor, Brian J ^b   Langley, Stephen J ^b   Woodcock, Ashley ^b   Kerstjens, Huib A M ^b   Postma, Dirkje S ^b   Danzig, Mel ^b   Cuss, Francis ^b   Pauwels, Romain A ^b  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b NONE

Author keywords

Anti human interleukin 5 antibody; Asthma; Eosinophil; Glucocorticosteroids; Interleukin 5

Indexed keywords

INTERLEUKIN 5 ANTIBODY; PLACEBO; SCH 55700; STEROID; UNCLASSIFIED DRUG;

ADULT; ARTICLE; ASTHMA; CELL COUNT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE EXACERBATION; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ACTIVITY; DRUG EFFECT; DRUG SAFETY; DRUG SCREENING; EOSINOPHIL; EVALUATION; FATIGUE; FEMALE; FORCED EXPIRATORY VOLUME; HEADACHE; HUMAN; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT;

ADULT; ANALYSIS OF VARIANCE; ANTI-ASTHMATIC AGENTS; ANTIBODIES, MONOCLONAL; ASTHMA; DOUBLE-BLIND METHOD; DRUG MONITORING; EOSINOPHILIA; EOSINOPHILS; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; IMMUNOGLOBULIN G; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAVENOUS; INTERLEUKIN-5; LEUKOCYTE COUNT; MALE; PILOT PROJECTS; SAFETY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 0038643527     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/rccm.200206-525OC     Document Type: Article

References (35)

1. Bousquet J, Jeffery PK, Busse WW, Johnson M, Vignola AM. Asthma: from bronchoconstriction to airways inflammation and remodeling. Am J Respir Crit Care Med 2000;161:1720-1745.
2. Rothenberg ME. Eosinophilia. N Engl J Med 1998;338:1592-1600.
3. Tavernier J, Plaetinck G, Guisez Y, Van der Heyden J, Kips J, Peleman R, Devos R. The role of IL-5 in the production and function of eosinophils. In: Whetton AD, Gordon JR, editors. Cell biochemistry. Vol. 7: Hematopoietic cell growth factors and their receptors. New York: Plenum Press; 2000. p. 321-361.
4. + T cells, eosinophils, and mast cells in bronchial biopsies obtained from atopic and non-atopic (intrinsic) asthmatics. J Immunol 1997;158:3539-3544.
5. Yasruel Z, Humbert M, Kotsimbos TC, Ploysongsang Y, Minshall E, Durham SR, Pfister R, Menz G, Tavernier J, Kay AB, et al. Membrane-bound and soluble α IL-5 receptor mRNA in the bronchial mucosa of atopic and nonatopic asthmatics. Am J Respir Crit Care Med 1997;155:1413-1418.
6. Shi HZ, Xiao CQ, Zhong D, Qin SM, Liu Y, Liang GR, Xu H, Chen YQ, Long XM, Xie ZF. Effect of inhaled interleukin-5 on airway hyper-reactivity and eosinophilia in asthmatics. Am J Respir Crit Care Med 1998;157:204-209.
7. Huston MM, Moore JP, Mettes HJ, Tavana G, Huston DP. Human B cells express IL-5 receptor messenger ribonucleic acid and respond to IL-5 with enhanced IgM production after mitogenic stimulation with Moraxella catarrhalis. J Immunol 1996;156:1392-13401.
8. Egan RW, Athwal D, Bodmer MW, Carter JM, Chapman RW, Chou CC, Cox MA, Emtage JS, Fernandez X, Genatt N, et al. Effect of SCH55700, a humanized monoclonal antibody to human interleukin-5, on eosinophilic responses and bronchial hyperreactivity. Arzneimittelforschung 1999;49:779-790.
9. Kips JC, O'Connor BJ, Langley SJ, Woodcock A, Kerstjens HAM, Postma DS, Danzig M, Cuss F, Pauwels RA. Results of a phase I trial with SCH55700, a humanized anti-IL-5 antibody, in severe persistent asthma [abstract]. Am J Respir Crit Care Med 2000;161:A505.
10. Kips JC, O'Connor BJ, Inman MD, Svensson K, Pauwels RA, O'Byrne PM. A long-term study of the antiinflammatory effect of low-dose budesonide plus formoterol versus high-dose budesonide in asthma. Am J Respir Crit Care Med 2000;161:996-1001.
11. Wood JL, Inman MD, Watson RM, Foley R, Denburg JA, O'Byrne PM. Changes in bone marrow inflammatory cell progenitors after inhaled allergen in asthmatic subjects. Am J Respir Crit Care Med 1998;157:99-105.
12. Wang J, Palmer K, Lotvall J, Milan S, Lei XF, Matthaei Ki, Gauldie J, Inman MD, Jordana M, Xing Z. Circulating, but not local lung, IL-5 is required for the development of antigen-induced airways eosinophilia. J Clin Invest 1998;102:1132-1141.
13. Minshall EM, Schleimer R, Cameron L, Minnicozzi M, Egan RW, Gutierrez-Ramos JC, Eidelman DH, Hamid Q. Interleukin-5 expression in the bone marrow of sensitized BALB/c mice after allergen challenge. Am J Respir Crit Care Med 1998;158:951-957.
14. Wood LJ, Sehmi R, Gauvreau GM, Watson RM, Foley R, Denburg JA, O'Byrne PM. An inhaled corticosteroid, budesonide, reduces baseline but not allergen-induced increases in bone marrow inflammatory cell progenitors in asthmatic subjects. Am J Respir Crit Care Med 1999;159:1457-1463.
15. Alexander AG, Barkans J, Moqbel R, Barnes NC, Kay AB, Corrigan CJ. Serum interleukin 5 concentrations in atopic and non-atopic patients with glucocorticoid-dependent chronic severe asthma. Thorax 1994;49:1231-1233.
16. Leckie MJ, ten Brinke A, Khan J, Diamant Z, O'Connor B, Walls CM, Mathur M, Cowley H, Chung KF, Djukanovic R, et al. Effects of an IL-5 blocking monoclonal antibody on eosinophils, airway hyperresponsiveness, and the late asthmatic response. Lancet 2000;356:2144-2148.
17. Mauser PJ, Pitman AM, Fernandez X, Foran SK, Adams GK, Kreutner W, Egan RW, Chapman RW. Effects of an antibody to interleukin-5 in a monkey model of asthma. Am J Respir Crit Care Med 1995;152:467-472.
18. Garlisi CG, Kung TT, Wang P, Minnicozzi M, Umland SP, Chapman RW, Stelts D, Crawley Y, Falcone A, Myers JG, et al. Effects of chronic anti-interleukin-5 monoclonal antibody treatment in a murine model of pulmonary inflammation. Am J Respir Cell Mol Bio 1999;20:248-255.
19. Zabeau L, Van der Heyden J, Broekaert D, Verhee A, Vandekerckhove J, Wu S-J, Chaiken I, Heinrich P, Behrmann I, Tavernier J. Neutralizing monoclonal antibodies can potentiate IL-5 signaling. Eur J Immunol 2001;31:1087-1097.
20. Takamoto M, Ovington KS, Behm CA, Sugane K, Young IG, Matthaei KI. Eosinophilia, parasite burden and lung damage in Toxocara canis infection in C57BL/6 mice genetically deficient in IL-5. Immunology 1997;90:511-517.
21. + T cells in the antitumor immune response. J Exp Med 1998;188:2357-2368.
22. Songun I, van de Velde CJ, Hermans J, Pals ST, Verspaget HW, Vis AN, Menon AG, Litvinov SV, Van Krieken JH. Expression of onco-proteins and the amount of eosinophilic and lymphocytic infiltrates can be used as prognostic factors in gastric cancer. Dutch Gastric Cancer Group (DGCG). Br J Cancer 1996;74:1783-1788.
23. Ono Y, Fujii M, Kameyama K, Otani Y, Sakurai Y, Kanzaki J. Expression of matrix metalloproteinase-1 mRNA related to eosinophilia and interleukin-5 gene expression in head and neck tumour tissue. Virchows Arch 1997;431:305-310.
24. Wenzel SE, Schwartz LB, Langmack EL, Halliday JL, Trudeau JB, Gibbs RL, Chu HW. Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. Am J Respir Crit Care Med 1999;160:1001-1008.
25. Flood-Page P, Menzies-Gow A, Compton C, Walls C, Barnes N, Robinson DS, Kay AB. Does anti-IL-5 deplete bronchial mucosal eosinophils in mild atopic asthma. J Allergy Clin Immunol 2002;108:743.
26. Hakonarson H, Maskeri N, Carter C, Grunstein MM. Regulation of Th1- and Th2-type cytokine expression and action in atopic asthmatic sensitized airway smooth muscle. J Clin Invest 1999;103:1077-1087.
27. Rizzo CA, Yang R, Greenfeder S, Egan RW, Pauwels RA, Hey JA. The IL-5 receptor on human bronchus selectively primes for hyperresponsiveness. J Allergy Clin Immunol 2002;109:404-409.
28. van Rensen ELJ, Stirling RG, Scheerens J, Staples K, Sterk PJ, Barnes PJ, Chung KF. Evidence for systemic rather than pulmonary effects of interleukin-5 administration in asthma. Thorax 2001;56:935-940.
29. Kips JC, Cuvelier CA, Pauwels RA. Effect of acute and chronic antigen inhalation on airway morphology and responsiveness in actively sensitized rats. Am Rev Respir Dis 1992;145:1306-1310.
30. Tournoy KG, Kips JC, Schou C, Pauwels RA. Airway eosinophilia is not a requirement for allergen-induced airway hyperresponsiveness. Clin Exp Allergy 2000;30:79-85.
31. Coyle AJ, Kohler G, Tsuyuki S, Brombacher F, Kopf M. Eosinophils are not required to induce airway hyperresponsiveness after nematode infection. Eur J Immunol 1998;28:2640-2647.
32. de Kluijver J, Evertse CE, Schrumpf JA, van der Veen H, Zwinderman AH, Hiemstra PS, Rabe KF, Sterk PJ. Asymptomatic worsening of airway inflammation during low-dose allergen exposure in asthma. Am J Respir Crit Care Med 2002;166:294-300.
33. Djukanovic R, Wilson JW, Britten KM, Wilson SJ, Walls AF, Roche WR, Howarth PH, Holgate ST. Quantitation of mast cells and eosinophils in the bronchial mucosa of symptomatic atopic asthmatics and healthy control subjects using immunohistochemistry. Am Rev Respir Dis 1990;142:863-871.
34. Rosi E, Ronchi MC, Grazzini M, Duranti R, Scano G. Sputum analysis, bronchial hyperresponsiveness, and airway function in asthma: results of a factor analysis. J Allergy Clin Immunol 1999;103:232-237.
35. O'Byrne PM, Inman MD, Parameswaran K. The trials and tribulations of IL-5, eosinophils, and allergic asthma. J Allergy Clin Immunol 2001;108:503-508.